Securities code: Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) securities abbreviation: Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) Announcement No.: 2022016
Zhejiang Anglikang Pharmaceutical Co.Ltd(002940)
Announcement on the bidding results of L-amlodipine besylate tablets participating in the procurement of drugs in Zhejiang Municipal United (Jinhua)
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Zhejiang Anglikang Pharmaceutical Co.Ltd(002940) (hereinafter referred to as “the company”) recently participated in the quotation of Zhejiang municipal joint (Jinhua) drug with quantity procurement (hereinafter referred to as “Zhejiang Province with quantity procurement”) carried out by the office of Zhejiang Jinhua pharmaceutical consumables centralized with quantity Procurement Alliance Committee, According to the list of drugs to be selected for Zhejiang provincial and Municipal United (Jinhua) drug with volume procurement published on March 2, 2022, the company’s product Levamlodipine besylate tablets was not selected for this Zhejiang provincial drug with volume procurement.
1、 Basic information of the company’s L-amlodipine besylate tablets
Drug name specification function indications
The indications of L-amlodipine besylate tablets are hypertension and angina pectoris according to 2.5mg and 5mg of L-amlodipine
Note: the specifications of levofloxacin oral normal release dosage form purchased by Zhejiang Municipal United (Jinhua) drugs are 2.5mg and 5mg.
2、 The impact on the company caused by the failure of L-amlodipine besylate tablets
At present, zoletipine (hereinafter referred to as zoletipine) is one of the core products of the company. From January to September 2021, the company’s operating revenue was 987 million yuan, of which the sales revenue of Zuo Yi was 452 million yuan, accounting for 45.80% of the company’s operating revenue in the first three quarters of 2021, and the sales revenue of Zuo Yi in Zhejiang was 159 million yuan, accounting for 16.11% of the company’s operating revenue in the first three quarters of 2021.
In this procurement with volume in Zhejiang Province, there is one enterprise to be selected, and the agreed procurement volume is about 217610000 tablets (calculated as 2.5mg), and the procurement cycle is 12 months. This failure will have a certain impact on the sales of Zuoyi products in Zhejiang in the next 12 months, and will bring new challenges to the future development of the company.
3、 Response measures of the company
The company’s L-amlodipine besylate tablets were not selected this time. On the one hand, the company will actively strive for the remaining consumption and share beyond the agreed procurement volume of public medical institutions in Zhejiang Province, urge the salesperson to strengthen the development of markets other than centralized procurement in Zhejiang Province (including private hospitals and retail terminals), and will continue to pay attention to the bidding process in other provinces, Study the medical insurance policies and Bidding Schemes of all provinces. On the other hand, the company will also increase investment in drug R & D, optimize the structure of projects under research, improve R & D and innovation ability, promote the registration and application of new products, actively find and develop new high value-added products, and gradually reduce the impact and pressure of centralized procurement policy on the single variety market in the future.
Please make careful decisions and pay attention to investment risks.
It is hereby announced.
Zhejiang Anglikang Pharmaceutical Co.Ltd(002940)
Board of directors
March 3, 2022
